<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00488787</url>
  </required_header>
  <id_info>
    <org_study_id>KET-003</org_study_id>
    <nct_id>NCT00488787</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Intranasal Ketamine for the Treatment of Postoperative Dental Pain</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of 10 mg, 30 mg, and 50 mg of Transnasal Ketamine Hydrochloride (PMI-100) for the Treatment of Postoperative Dental Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Javelin Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Javelin Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Once patients' postoperative pain intensity reaches a moderate-to-severe level, they are
      randomized to receive intranasal ketamine or placebo. Patients remain in the study unit for 3
      hours post administration and assess pain intensity and pain relief throughout the 3 hour
      postoperative period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">April 2001</completion_date>
  <primary_completion_date type="Actual">April 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total pain relief over 0-3 hours following dosing</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>other pain assessments</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal ketamine low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal ketamine medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal ketamine high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal ketamine</intervention_name>
    <description>low dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal ketamine</intervention_name>
    <description>medium dose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal ketamine</intervention_name>
    <description>high dose</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy patients at least 16 years of age requiring two or more third molar
             extractions

        Exclusion Criteria:

          -  Less than 16 years old

          -  Other exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle Christensen, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jean Brown Associates</affiliation>
  </overall_official>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2007</study_first_submitted>
  <study_first_submitted_qc>June 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2007</study_first_posted>
  <last_update_submitted>February 5, 2008</last_update_submitted>
  <last_update_submitted_qc>February 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Javelin Pharmaceuticals</name_title>
    <organization>Javelin Pharmaceuticals</organization>
  </responsible_party>
  <keyword>dental</keyword>
  <keyword>surgery</keyword>
  <keyword>analgesia</keyword>
  <keyword>2-4 impacted third molars</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

